Should I buy or sell Lumos Pharma stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lumos Pharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LUMO shares. View LUMO analyst ratings or view top-rated stocks .

What is Lumos Pharma's stock price target for 2024?

3 Wall Street analysts have issued 12 month price targets for Lumos Pharma's stock. Their LUMO share price targets range from $10.00 to $28.00. On average, they predict the company's stock price to reach $18.00 in the next twelve months. This suggests a possible upside of 595.0% from the stock's current price. View analysts price targets for LUMO or view top-rated stocks among Wall Street analysts .

How have LUMO shares performed in 2024?

Lumos Pharma's stock was trading at $3.18 on January 1st, 2024. Since then, LUMO shares have decreased by 18.6% and is now trading at $2.59. View the best growth stocks for 2024 here .

When is Lumos Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our LUMO earnings forecast .

How were Lumos Pharma's earnings last quarter?

Lumos Pharma, Inc. (NASDAQ:LUMO) issued its quarterly earnings data on Thursday, March, 7th. The company reported ($1.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.18) by $0.01. The firm had revenue of $0.83 million for the quarter, compared to the consensus estimate of $0.01 million. Lumos Pharma had a negative net margin of 1,659.39% and a negative trailing twelve-month return on equity of 85.63%. During the same quarter in the previous year, the business earned ($0.98) earnings per share.

What other stocks do shareholders of Lumos Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lumos Pharma investors own include Advanced Micro Devices (AMD) , Agilent Technologies (A) , Air Lease (AL) , Bionano Genomics (BNGO) , Chimerix (CMRX) , Compagnie de Saint-Gobain (CODYY) and

How do I buy shares of Lumos Pharma?

Shares of LUMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:LUMO

Lumos Pharma (LUMO) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free LUMO Stock Alerts

$2.59

-0.03 (-1.15%)

(As of 04/19/2024 ET)

Compare

Today's Range: $2.53
▼
$2.83
50-Day Range: $2.45
▼
$3.15
52-Week Range: $2.41
▼
$4.55

Volume: 12,306 shs
Average Volume: 20,725 shs
Market Capitalization: $21.03 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $18.00

Get Lumos Pharma alerts:

Lumos Pharma MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 595.0% Upside
$18.00 Price Target
Short Interest: Bearish
5.94% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$7,460 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.80) to ($2.00) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.46 out of 5 stars

Medical Sector

703rd out of 911 stocks

Pharmaceutical Preparations Industry

310th out of 411 stocks

3.5

Analyst's Opinion

Consensus Rating
Lumos Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Lumos Pharma has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
5.94% of the float of Lumos Pharma has been sold short.
Short Interest Ratio / Days to Cover
Lumos Pharma has a short interest ratio ("days to cover") of 13.2, which indicates bearish sentiment.
Change versus previous month
Short interest in Lumos Pharma has recently decreased by 2.08%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Lumos Pharma does not currently pay a dividend.
Dividend Growth
Lumos Pharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LUMO.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Lumos Pharma this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for LUMO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Lumos Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,460.00 in company stock.
Percentage Held by Insiders
23.70% of the stock of Lumos Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 33.99% of the stock of Lumos Pharma is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Lumos Pharma are expected to grow in the coming year, from ($2.80) to ($2.00) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Lumos Pharma is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Lumos Pharma is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Lumos Pharma has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Lumos Pharma Stock (NASDAQ:LUMO)

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its primary product candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 3 clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.

LUMO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

LUMO Stock News Headlines

April 18, 2024 | globenewswire.com

Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings

March 21, 2024 | markets.businessinsider.com

Lumos Pharma’s LUM-201 Receives ‘Buy’ Rating on Strong Market Position and Promising Trial Outcomes

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 20, 2024 | globenewswire.com

Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042

March 11, 2024 | sg.news.yahoo.com

BAT set to sell stake in India's ITC stake as soon as this week, Bloomberg reports

March 10, 2024 | finance.yahoo.com

Lumos Pharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

March 9, 2024 | seekingalpha.com

Lumos Pharma, Inc. (LUMO) Q4 2023 Earnings Call Transcript

March 8, 2024 | finanznachrichten.de

Lumos Pharma, Inc.: Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 8, 2024 | finance.yahoo.com

Lumos Pharma, Inc. (NASDAQ:LUMO) Q4 2023 Earnings Call Transcript

March 8, 2024 | uk.finance.yahoo.com

Q4 2023 Lumos Pharma Inc Earnings Call

March 7, 2024 | investorplace.com

LUMO Stock Earnings: Lumos Pharma Misses EPS for Q4 2023

March 7, 2024 | benzinga.com

Lumos Pharma: Q4 Earnings Insights

March 7, 2024 | globenewswire.com

Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update

March 6, 2024 | benzinga.com

Earnings Preview: Lumos Pharma

March 6, 2024 | msn.com

Lumos Pharma FY 2023 Earnings Preview

February 28, 2024 | finance.yahoo.com

AxoSim Appoints Two Biotech Industry Veterans as Co-Chairs of Its Board of Directors

February 26, 2024 | globenewswire.com

Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024

February 21, 2024 | msn.com

Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates

February 5, 2024 | finance.yahoo.com

Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference

February 5, 2024 | finance.yahoo.com

Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference

February 5, 2024 | finance.yahoo.com

Is Lumos Pharma (NASDAQ:LUMO) In A Good Position To Invest In Growth?

January 4, 2024 | marketwatch.com

Lumos Pharma Elevates Pitukcheewanont to Medical Chief

January 4, 2024 | msn.com

Lumos Pharma promotes Pisit Pitukcheewanont to chief medical officer

December 22, 2023 | benzinga.com

Lumos Pharma Stock (NASDAQ:LUMO) Dividends: History, Yield and Dates

December 8, 2023 | markets.businessinsider.com

Bullish Outlook: Buy Rating on Lumos Pharma on Promising LUM-201 Trials for Pediatric Growth Deficiency

November 21, 2023 | finance.yahoo.com

Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency

See More Headlines

Receive LUMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lumos Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/07/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:LUMO
CUSIP: N/A
CIK: 1126234
Web: www.lumos-pharma.com
Phone: (512) 215-2630
Fax: 515-296-3520
Employees: 33
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $18.00
High Stock Price Target: $28.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +587.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.19)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-34,030,000.00
Net Margins: -1,659.39%
Pretax Margin: -1,660.80%
Return on Equity: -85.63%
Return on Assets: -65.30%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.69
Quick Ratio: 5.69

Sales & Book Value

Annual Sales: $2.05 million
Price / Sales: 10.38
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.45 per share
Price / Book: 0.76

Miscellaneous

Outstanding Shares: 8,120,000
Free Float: 6,193,000
Market Cap: $21.27 million
Optionable: Not Optionable
Beta: 0.65

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Mr. Richard J. Hawkins (Age 75)
Founder, CEO & Chairman
Comp: $975.72k
Dr. John C. McKew Ph.D. (Age 60)
Chief Scientific Officer & President
Comp: $943.46k
Ms. Lori D. Lawley CPA (Age 40)
CFO & Principal Accounting Officer
Comp: $596.57k
Lisa Miller
Senior Director of Investor Relations
Mr. Bradley J. Powers J.D. (Age 45)
Chief Compliance Officer & General Counsel
Comp: $677.08k
Mr. Aaron Schuchart B.B.A. (Age 58)
CPA, M.B.A., Chief Business Officer
Dr. Pisit Pitukcheewanont FAAP
M.D., Chief Medical Officer
Mr. Eddie L. Varnado M.B.A.
Corporate Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LUMO Stock Analysis - Frequently Asked Questions

Should I buy or sell Lumos Pharma stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lumos Pharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LUMO shares.
View LUMO analyst ratings or view top-rated stocks.
What is Lumos Pharma's stock price target for 2024?: 3 Wall Street analysts have issued 12 month price targets for Lumos Pharma's stock. Their LUMO share price targets range from $10.00 to $28.00. On average, they predict the company's stock price to reach $18.00 in the next twelve months. This suggests a possible upside of 595.0% from the stock's current price.
View analysts price targets for LUMO or view top-rated stocks among Wall Street analysts.
How have LUMO shares performed in 2024?: Lumos Pharma's stock was trading at $3.18 on January 1st, 2024. Since then, LUMO shares have decreased by 18.6% and is now trading at $2.59.
View the best growth stocks for 2024 here.
When is Lumos Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our LUMO earnings forecast.

How were Lumos Pharma's earnings last quarter?: Lumos Pharma, Inc. (NASDAQ:LUMO) issued its quarterly earnings data on Thursday, March, 7th. The company reported ($1.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.18) by $0.01. The firm had revenue of $0.83 million for the quarter, compared to the consensus estimate of $0.01 million. Lumos Pharma had a negative net margin of 1,659.39% and a negative trailing twelve-month return on equity of 85.63%. During the same quarter in the previous year, the business earned ($0.98) earnings per share.
What other stocks do shareholders of Lumos Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Lumos Pharma investors own include Advanced Micro Devices (AMD), Agilent Technologies (A), Air Lease (AL), Bionano Genomics (BNGO), Chimerix (CMRX), Compagnie de Saint-Gobain (CODYY) and
How do I buy shares of Lumos Pharma?: Shares of LUMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LUMO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Lumos Pharma (LUMO) Stock Price, News & Analysis

Lumos Pharma MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Lumos Pharma Stock (NASDAQ:LUMO)

LUMO Stock Price History

LUMO Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

LUMO Stock Analysis - Frequently Asked Questions

Overall MarketRank^™